BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference

Rhea-AI Summary

BeiGene, Ltd. (NASDAQ: BGNE) announced its participation in the J.P. Morgan 39th Annual Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. Investors can access a live webcast through BeiGene's website, with an archived replay available for 90 days post-event. As a global biotechnology company, BeiGene focuses on developing innovative medicines, particularly in oncology, with products like BRUKINSA and tislelizumab currently marketed. The company employs over 5,000 staff across multiple regions, committed to improving patient outcomes.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021 at 5:20 p.m. ET.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA^® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005294/en/

FAQ

When is BeiGene presenting at the J.P. Morgan 39th Annual Healthcare Conference?

BeiGene will present at the J.P. Morgan 39th Annual Healthcare Conference on January 14, 2021, at 5:20 p.m. ET.

How can I watch BeiGene's presentation at the healthcare conference?

You can access a live webcast of BeiGene's presentation from the investors section of their website.

What products does BeiGene market?

BeiGene markets the oncology products BRUKINSA (zanubrutinib) and tislelizumab, among others.

How many employees does BeiGene have?

BeiGene has over 5,000 employees worldwide.

Where can I find more information about BeiGene?

More information about BeiGene can be found on their official website at www.beigene.com.